Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$0.54 USD
+0.04 (8.00%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Sensei Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -34.10 | -48.59 | -36.79 | -20.10 | -16.74 |
Depreciation/Amortization & Depletion | 1.35 | 1.35 | 0.69 | 1.79 | 1.47 |
Net Change from Assets/Liabilities | -4.33 | 1.01 | 0.12 | -0.40 | 3.47 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.06 | 7.21 | 5.73 | 1.01 | 3.23 |
Net Cash From Operating Activities | -32.02 | -39.03 | -30.26 | -17.71 | -8.57 |
Property & Equipment | -0.01 | -0.31 | -1.71 | -1.21 | -0.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | -0.20 | 0.00 |
Investments | 38.43 | 50.26 | -141.41 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 38.41 | 49.95 | -143.12 | -1.40 | -0.05 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -10.38 | 0.24 | 164.20 | 37.03 | 0.15 |
Issuance (Repayment) of Debt | -0.76 | -0.63 | 0.00 | 0.57 | 8.10 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.03 | 0.10 | -0.26 | -2.15 | -0.03 |
Net Cash from Financing Activities | -11.17 | -0.29 | 163.94 | 35.45 | 8.22 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.78 | 10.64 | -9.44 | 16.35 | -0.40 |
Cash at Beginning of Period | 17.80 | 7.16 | 16.60 | 0.25 | 0.65 |
Cash at End of Period | 13.01 | 17.80 | 7.16 | 16.60 | 0.25 |
Diluted Net EPS | -1.22 | -1.58 | -1.33 | -12.53 | NA |
Fiscal Year End for Sensei Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.13 | -7.99 | -34.10 | -26.69 | -19.56 |
Depreciation/Amortization & Depletion | 0.66 | 0.22 | 1.35 | 1.02 | 0.69 |
Net Change from Assets/Liabilities | -1.34 | -1.43 | -4.33 | -3.93 | -4.91 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.41 | 1.59 | 5.06 | 3.74 | 2.58 |
Net Cash From Operating Activities | -13.41 | -7.62 | -32.02 | -25.86 | -21.20 |
Property & Equipment | -0.15 | -0.04 | -0.01 | -0.01 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 12.82 | 5.81 | 38.43 | 30.16 | 21.85 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 12.68 | 5.77 | 38.41 | 30.15 | 21.84 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | -10.38 | -10.13 | -7.79 |
Issuance (Repayment) of Debt | -0.40 | -0.20 | -0.76 | -0.57 | -0.38 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.01 | -0.01 | -0.03 | -0.05 | -0.05 |
Net Cash from Financing Activities | -0.39 | -0.21 | -11.17 | -10.74 | -8.21 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.12 | -2.06 | -4.78 | -6.45 | -7.57 |
Cash at Beginning of Period | 13.01 | 13.01 | 17.80 | 17.80 | 17.80 |
Cash at End of Period | 11.89 | 10.96 | 13.01 | 11.34 | 10.23 |
Diluted Net EPS | -0.28 | -0.32 | -0.30 | -0.28 | -0.31 |